Veterans test remote walking programs to ease leg pain from clogged arteries

NCT ID NCT06033924

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests two home-based walking programs for veterans with peripheral artery disease (PAD), a condition that causes leg pain when walking. Participants will either use a website, have telehealth coaching, or get usual care. The goal is to see if these programs help them walk longer distances and improve quality of life. The study will enroll 225 veterans and follow them for 36 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
walking program
What this could lead to
If successful, this could show that telehealth or web-based coaching helps veterans with PAD walk farther and feel better without needing in-person visits.
What could go wrong
This is a behavioral study with no drug or device, so benefits may be modest. Results depend on participant motivation and may not apply to all PAD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Birmingham VA Medical Center, Birmingham, AL

    NOT_YET_RECRUITING

    Birmingham, Alabama, 35233-1927, United States

  • Rocky Mountain Regional VA Medical Center, Aurora, CO

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045-7211, United States

  • VA Palo Alto Health Care System, Palo Alto, CA

    RECRUITING

    Palo Alto, California, 94304-1207, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.